冠心病患者血小板CD31表达水平及超敏C反应蛋白的测定及其意义

Expression levels of platelet CD31 and hs-CRP in patients with coronary heart disease

关键词:  冠心病  CD31  hs-CRP  流式细胞术

Key words:  coronary heart disease  CD31  hs-CRP  flow cytometry

摘要:

目的　探讨血小板CD31（又称血小板内皮细胞粘分子-1，PECAM-1）在冠心病（CHD）诊断中的临床价值。方法　选取2015年10月至2016年11月大连医科大学附属第二医院心内科住院患者60例。其中急性冠脉综合征（ACS）组30例（UA 16例，AMI 14例），稳定型心绞痛（SA）组5例及非冠心病（non-CHD）组25例。通过流式细胞术结合单克隆抗体技术检测其血小板CD31的表达水平，用免疫散射比浊法测定血清中hs-CRP含量，并分析二者表达水平的相关性。结果　ACS组、SA组、non-CHD组的CD31表达水平分别为（95.24±6.29）%、（57.38±10.27 ）%、（54.83±8.73）%， ACS组明显高于SA组和non-CHD组（P<0.01），SA组和no-CHD组间比较差异无显著性（P>0.05）。 ACS组中的UA亚组和AMI亚组CD31表达水平分别为（94.10±6.90） %、（96.54±5.47） %，差异无显著性（P>0.05）。ACS组、SA组、non-CHD组的hs-CRP水平分别为（6.15±2.62 ）mg/L、（0.93±0.51 ）mg/L、（0.76±0.52） mg/L，ACS组明显高于SA组和non-CHD组（P<0.01），SA组和non-CHD组间比较差异无显著性（P>0.05）。ACS组中的UA亚组和AMI亚组hs-CRP水平分别为（5.69±2.32） mg/L、（6.68±2.92） mg/L，差异无显著性（P>0.05）。CHD患者血小板CD31表达水平和血清hs-CRP水平呈明显正相关(r=0.681, P<0.01)。结论　CHD患者血小板CD31表达水平与血清hs-CRP水平呈正相关，监测CHD患者血小板CD31表达水平，可能对ACS的诊断提供一定的参考价值。

Abstract:

Objective To detect and analyze the expression level of platelet CD31（also known as platelet endothelial cell adhesion molecule-1, PECAM-1) in patients with coronary heart disease (CHD). Methods Sixty patients were selected from the Department of Cardiology at the second affiliated hospital of dalian medical university from October 2015 to November 2016. Among them, 30 cases (UA 16 cases, AMI 14 cases) were divided into the acute coronary syndrome (ACS) group, 5 cases into the stable angina (SA) group, and 25 cases into the non-CHD group. Flow cytometry and monoclonal antibody technology were used to detect the expression level of platelet CD31 in the blood samples. Serum level of hs-CRP was detected using immune nephelometry by Hitachi 7600 automatic biochemical analyzer. The correlation between the two levels was also analyzed. Results The expression levels of platelet CD31 in the ACS group, the SA group and the non-CHD group were (95.24±6.29)%,（57.38±10.27）%, and （54.83±8.73）%, respectively. The expression level of platelet CD31was significantly higher in the ACS group than those in the SA group and the non-CHD group (P<0.01), and was similar between the SA group and the non-CHD group (P>0.05). The expression levels of platelet CD31 of UA subgroup and AMI subgroup in the ACS group were (94.10±6.90)% and (96.54±5.47)%, respectively. There was no significant difference between the two subgroup (P>0.05). The hs-CRP levels in the ACS group, the SA group and the non-CHD group were (6.15±2.62) mg/L, (0.93±0.51) mg/L, and (0.76±0.52) mg/L, respectively. Serum level of hs-CRP was significantly higher in the ACS group than those in the SA group and the non-CHD group ( P<0.01), and was similar between the SA group and the non-CHD group (P>0.05). The hs-CRP levels of UA subgroup and AMI subgroup in the ACS group were (5.69±2.32） mg/L and (6.68±2.92) mg/L, respectively. There was no significant difference between the two subgroup (P>0.05). The expression level of platelet CD31 and serum level of hs-CRP were positively correlated (r=0.681, P<0.01). Conclusion In CHD patients, the expression levels of platelet CD31 and serum hs-CRP are positively correlated. Measurement of the expression level of platelet CD31 in CHD patients may help to diagnose ACS.